 | • レポートコード：MRC2302B034 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、237ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に6,291.00百万ドルであった世界の神経障害性疼痛治療市場規模が、2022年に6,974.20百万ドルになり、2027年には11,840.08百万ドルまで、年平均11.11%で成長すると予測しています。本レポートでは、神経障害性疼痛治療の世界市場について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疼痛種類別（閉じ込め神経障害、末梢神経障害、幻肢神経障害、帯状疱疹後神経痛(PHN)、その他）分析、疾患別（化学療法誘発性末梢神経障害、糖尿病性神経障害、脊柱管狭窄症）分析、流通別（オンライン薬局、小売薬局＆ドラッグストア）分析、エンドユーザー別（クリニック、病院）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でお届けします。なお、本書には、Abbott Laboratories、Assertio Therapeutics Inc.、Astellas Pharma Inc.、AstraZeneca Plc、Aurobindo Pharma Ltd.、Baxter International Inc.、Biogen Inc.、Bristol Myers Squibb Company、Depomed, Inc.、Dr. Reddy’s Laboratories Ltd.、Eli Lilly and Company、Endo International Plc、GlaxoSmithKline Plc、Johnson and Johnson Services, Inc.、Mallinckrodt Pharmaceuticals、Novartis AG、Pfizer Inc.、Sanofi、Sun Pharmaceutical Industries Ltd、Teva Pharmaceutical Industries Ltd.、VistaGen Therapeutics Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の神経障害性疼痛治療市場規模：疼痛種類別 - 閉じ込め神経障害の市場規模 - 末梢神経障害の市場規模 - 幻肢神経障害の市場規模 - 帯状疱疹後神経痛(PHN)の市場規模 - その他疼痛の市場規模 ・世界の神経障害性疼痛治療市場規模：疾患別 - 化学療法誘発性末梢神経障害の市場規模 - 糖尿病性神経障害の市場規模 - 脊柱管狭窄症の市場規模 ・世界の神経障害性疼痛治療市場規模：流通別 - オンライン薬局チャネルの市場規模 - 小売薬局＆ドラッグストアチャネルの市場規模 ・世界の神経障害性疼痛治療市場規模：エンドユーザー別 - クリニックにおける市場規模 - 病院における市場規模 ・世界の神経障害性疼痛治療市場規模：地域別 - 南北アメリカの神経障害性疼痛治療市場規模 アメリカの神経障害性疼痛治療市場規模 カナダの神経障害性疼痛治療市場規模 ブラジルの神経障害性疼痛治療市場規模 ... - アジア太平洋の神経障害性疼痛治療市場規模 日本の神経障害性疼痛治療市場規模 中国の神経障害性疼痛治療市場規模 インドの神経障害性疼痛治療市場規模 韓国の神経障害性疼痛治療市場規模 台湾の神経障害性疼痛治療市場規模 ... - ヨーロッパ/中東/アフリカの神経障害性疼痛治療市場規模 イギリスの神経障害性疼痛治療市場規模 ドイツの神経障害性疼痛治療市場規模 インドの神経障害性疼痛治療市場規模 フランスの神経障害性疼痛治療市場規模 ロシアの神経障害性疼痛治療市場規模 ... - その他地域の神経障害性疼痛治療市場規模 ・競争状況 ・企業情報 |
The Global Neuropathy Pain Treatment Market size was estimated at USD 6,291.00 million in 2021 and expected to reach USD 6,974.20 million in 2022, and is projected to grow at a CAGR 11.11% to reach USD 11,840.08 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Neuropathy Pain Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Pain Type, the market was studied across Coccydynia, Entrapment Neuropathy, Foot Pain, Peripheral Neuropathy, Phantom Limb Neuropathy, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, and Trigeminal Neuralgia.
Based on Indication, the market was studied across Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Spinal Stenosis.
Based on Treatment, the market was studied across Drugs and Therapy. The Drugs is further studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
Based on Distribution Channel, the market was studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
Based on End-User, the market was studied across Clinics and Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neuropathy Pain Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuropathy Pain Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuropathy Pain Treatment Market, including Abbott Laboratories, Assertio Therapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Biogen Inc., Bristol Myers Squibb Company, Depomed, Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson Services, Inc., Mallinckrodt Pharmaceuticals, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., and VistaGen Therapeutics Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Neuropathy Pain Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuropathy Pain Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuropathy Pain Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Neuropathy Pain Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Neuropathy Pain Treatment Market?
6. What is the market share of the leading vendors in the Global Neuropathy Pain Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Neuropathy Pain Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in neuropathic pain among population
5.1.1.2. Increasing global healthcare expenditure
5.1.1.3. Growing number of neuropathic pain relievers and over-the-counter products
5.1.2. Restraints
5.1.2.1. Limited awareness of available treatment options
5.1.3. Opportunities
5.1.3.1. Introduction of novel pain treatment alternatives
5.1.3.2. Programs and initiatives focusing on palliative care
5.1.4. Challenges
5.1.4.1. Complexity in identifying the treatment suitable for neuropathic pains in a patient
5.2. Cumulative Impact of COVID-19
6. Neuropathy Pain Treatment Market, by Pain Type
6.1. Introduction
6.2. Coccydynia
6.3. Entrapment Neuropathy
6.4. Foot Pain
6.5. Peripheral Neuropathy
6.6. Phantom Limb Neuropathy
6.7. Post Herpetic Neuralgia (PHN)
6.8. Post Traumatic Neuropathy
6.9. Trigeminal Neuralgia
7. Neuropathy Pain Treatment Market, by Indication
7.1. Introduction
7.2. Chemotherapy-Induced Peripheral Neuropathy
7.3. Diabetic Neuropathy
7.4. Spinal Stenosis
8. Neuropathy Pain Treatment Market, by Treatment
8.1. Introduction
8.2. Drugs
8.3.1. Antidepressant Drugs Type
8.3.2.1. Serotonin Noradrenaline
8.3.2.2. Tricyclic Antidepressants
8.3.2. Medication Type
8.3.3. Multimodal Therapy
8.3.4. NSAIDs Type
8.3.5.1. Ibuprofen
8.3.5.2. Naproxen
8.3. Therapy
9. Neuropathy Pain Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Online Pharmacies
9.3. Retail Pharmacies & Drug Stores
10. Neuropathy Pain Treatment Market, by End-User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
11. Americas Neuropathy Pain Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Neuropathy Pain Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Neuropathy Pain Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Assertio Therapeutics Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Astellas Pharma Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. AstraZeneca Plc
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Aurobindo Pharma Ltd.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Baxter International Inc.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Biogen Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Bristol Myers Squibb Company
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Depomed, Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Dr. Reddy’s Laboratories Ltd.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Eli Lilly and Company
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Endo International Plc
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. GlaxoSmithKline Plc
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Johnson and Johnson Services, Inc.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Mallinckrodt Pharmaceuticals
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Novartis AG
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Pfizer Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Sanofi
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Sun Pharmaceutical Industries Ltd
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Teva Pharmaceutical Industries Ltd.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. VistaGen Therapeutics Inc.
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing